10-Q: CEL-SCI Reports Q1 2024 Results, Focuses on Multikine Approval Strategy

CEL-SCI Corporation reported its financial results for the quarter ended December 31, 2023, and provided updates on its regulatory strategy for Multikine.

Summary

• CEL-SCI Corporation reported a net loss of $6.7 million for the three months ended December 31, 2023, compared to a net loss of $8.0 million for the same period in 2022.
• Research and development expenses decreased by 19% to $4.4 million, while general and administrative expenses decreased by 6% to $2.1 million.
• The company's cash and cash equivalents decreased to $3.2 million from $4.1 million at the end of the previous quarter.
• CEL-SCI is focusing on obtaining regulatory approval for Multikine, particularly in Europe and the UK, based on Phase III trial data showing a significant survival benefit in a specific target population.
• The company is also planning to initiate a confirmatory study in 2024 to support accelerated approval in the U.S.
• The company raised approximately $5 million through a public offering of common stock in November 2023 and $7.8 million in February 2024.
• The company has incurred approximately $64.5 million in direct costs for the Phase 3 clinical trial of Multikine as of December 31, 2023, and estimates an additional $0.7 million will be required to complete the trial and file the clinical study report.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Multikine's potential, highlighting significant survival benefits in a target population. However, the company's financial situation and the need for additional funding temper the overall sentiment.

Positives

• Multikine showed a significant survival benefit in a specific target population, with a 28.6% absolute 5-year overall survival benefit.
• The company has identified a specific target population for Multikine treatment based on Phase III trial data and biological mechanisms.
• The company is actively pursuing regulatory approval for Multikine in multiple regions.
• The company successfully raised capital through a public offering of common stock.
• The company has a co-development agreement with Ergomed, which has contributed $11.9 million towards the Phase 3 clinical trial.

Negatives

• The company reported a net loss of $6.7 million for the quarter ended December 31, 2023.
• The company's cash and cash equivalents decreased to $3.2 million.
• The company has a history of recurring losses and has stated there is substantial doubt about its ability to continue as a going concern.
• The company's disclosure controls and procedures were not effective as of December 31, 2023 due to material weaknesses.

Risks

• The company's ability to raise additional capital is uncertain and dependent on market conditions.
• The company's ability to obtain regulatory approval for Multikine is not guaranteed.
• The company has a history of recurring losses and may need to curtail operations if it cannot raise sufficient funds.
• The company's disclosure controls and procedures were not effective as of December 31, 2023 due to material weaknesses.
• The company is dependent on the proceeds from the sale of its securities to meet its liquidity and capital requirements.

Future Outlook

CEL-SCI plans to seek immediate approval for Multikine based on existing data, using conditional approval pathways with a follow-on confirmatory study. The company intends to start a confirmatory trial in 2024 to support accelerated approval in the U.S. The company is also seeking scientific advice in Europe and the UK.

Management Comments

• CEL-SCI believes that the Phase III clinical trial demonstrated that Multikine caused tumors to reduce in size and/or caused the disease to downstage within just a few weeks of treatment before surgery.
• CEL-SCI believes that patients with tumors having low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patients immune system.
• CEL-SCI believes that the data generated to date already presents a compelling patient need in the target population that justifies immediate access to Multikine.

Industry Context

The document highlights the growing market for cancer immunotherapies and positions Multikine as a unique therapy given before surgery, targeting a specific patient population with low PD-L1 expression, differentiating it from checkpoint inhibitors like Keytruda and Opdivo.

Comparison to Industry Standards

• The document compares Multikine to checkpoint inhibitors like Keytruda and Opdivo, noting that those drugs work best on tumors with high PD-L1 expression, while Multikine is targeted at tumors with low PD-L1 expression.
• The document mentions that the global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, indicating the potential market size for Multikine.
• The document states that the current standard of care for the target population provides only about a 50/50 chance of surviving five years, while Multikine could increase that survival rate to over 70%, highlighting the potential improvement over existing treatments.

Related Party Transactions

• On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company's CEO, Geert Kersten, is a beneficiary.

Stakeholder Impact

• Shareholders may be impacted by the company's need to raise additional capital and the potential for dilution.
• Employees may be impacted by the company's financial situation and the potential for operational changes.
• Patients with head and neck cancer may benefit from the potential approval of Multikine.
• Creditors may be impacted by the company's financial situation and its ability to repay debts.

Next Steps

• CEL-SCI plans to provide the new data to the FDA in Q1 2024.
• CEL-SCI plans to ask for conditional approval in Canada under their Notice of Compliance with Conditions (NOC/C) pathway.
• CEL-SCI plans to start a confirmatory trial as soon as possible in 2024 and will then seek accelerated approval in the U.S.
• CEL-SCI has submitted requests for Scientific Advice in Europe and the UK and are hopeful for meetings in H1 2024.

Key Dates

Keywords

Multikine, Immunotherapy, Head and Neck Cancer, Clinical Trial, Regulatory Approval, Survival Benefit, PD-L1, Phase III, CEL-SCI, Biotechnology